BEDFORD, Mass., June
18, 2015 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX)
announced today that it has priced its previously announced private
offering of $1.0 billion aggregate
principal amount of 5.250% senior notes due 2022 at an issue price
of $1,000 per $1,000. The 2022 notes will be unsecured
obligations of the Company and will be guaranteed by certain of its
direct and indirect subsidiaries. The offering is expected to close
on July 2, 2015, subject to customary
closing conditions.
Hologic intends to use the net proceeds of the offering, plus
available cash, to redeem its outstanding 6.25% senior notes due
2020 in the aggregate principal amount of $1.0 billion.
The 2022 notes will not be registered under the Securities Act
of 1933, as amended, or any state securities laws. Unless so
registered, the securities may not be offered or sold in
the United States except pursuant
to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable
state securities laws. The 2022 notes are being offered only to
qualified institutional buyers in reliance on Rule 144A under the
Securities Act, and outside the United
States in accordance with Regulation S under the Securities
Act.
This press release is neither an offer to sell nor a
solicitation of an offer to buy any of these securities, nor shall
there be any offer, solicitation or sale of these securities in any
jurisdiction where the offer, solicitation or sale is not
permitted. This press release shall not constitute a notice of
redemption with respect to the 6.25% senior notes due 2020.
Forward-Looking Statements
This press release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions. Such
statements include, without limitation, the Company's intention to
issue the 2022 notes and the use of proceeds of the offering. These
forward-looking statements are subject to known and unknown risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. The
offering may also be adversely affected by prevailing credit
markets, which have been subject to significant volatility, or
adverse changes to Hologic's business or prospects. Hologic cannot
assure it will complete the issuance of the 2022 notes, on
favorable terms, if at all. The risks included above are not
exhaustive. Other factors that could adversely affect the Company's
business and prospects are described in the filings made by Hologic
with the SEC. Hologic expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contact
Michael Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-announces-pricing-of-offering-of-10-billion-aggregate-principal-amount-of-5250-senior-notes-due-2022-300101821.html
SOURCE Hologic, Inc.